Nothing Special   »   [go: up one dir, main page]

BR112012033349A2 - tratamento de queloide - Google Patents

tratamento de queloide

Info

Publication number
BR112012033349A2
BR112012033349A2 BR112012033349A BR112012033349A BR112012033349A2 BR 112012033349 A2 BR112012033349 A2 BR 112012033349A2 BR 112012033349 A BR112012033349 A BR 112012033349A BR 112012033349 A BR112012033349 A BR 112012033349A BR 112012033349 A2 BR112012033349 A2 BR 112012033349A2
Authority
BR
Brazil
Prior art keywords
keloid
skin
alanyl glutamine
treatment
keloid scars
Prior art date
Application number
BR112012033349A
Other languages
English (en)
Inventor
Adebola O E Obayan
Brenda Collen Joyce Yuzdepski
Sanjeev Singh
Original Assignee
Adetherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adetherapeutics filed Critical Adetherapeutics
Publication of BR112012033349A2 publication Critical patent/BR112012033349A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

tratamento de queloide. devido a um interesse existente há muito tempo na redução de cicatrizes, a alanil-glutamina foi testada quanto à capacidade de tratar cicatrizes de queloides, apesar das dificuldades associadas com a liberação dos compostos acima de certo limite de tamanho através da barreira da pele até a derme, onde se forma nova pele. surpreendentemente, verificou-se que uma formulação de aplicação dérmica de alanil-glutamina era efetiva na redução da gravidade e/ou na prevenção da formação de cicatrizes de queloides.
BR112012033349A 2010-06-28 2011-06-28 tratamento de queloide BR112012033349A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35905310P 2010-06-28 2010-06-28
PCT/CA2011/050396 WO2012000113A1 (en) 2010-06-28 2011-06-28 Keloid treatment

Publications (1)

Publication Number Publication Date
BR112012033349A2 true BR112012033349A2 (pt) 2016-10-11

Family

ID=45401271

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033349A BR112012033349A2 (pt) 2010-06-28 2011-06-28 tratamento de queloide

Country Status (14)

Country Link
US (1) US20140005116A1 (pt)
EP (1) EP2585090A4 (pt)
JP (1) JP2013533867A (pt)
KR (1) KR20130089174A (pt)
CN (1) CN103002903B (pt)
AU (1) AU2011274224A1 (pt)
BR (1) BR112012033349A2 (pt)
CA (1) CA2804413A1 (pt)
CO (1) CO6680624A2 (pt)
HK (1) HK1183626A1 (pt)
MX (1) MX2013000107A (pt)
RU (1) RU2578426C2 (pt)
WO (1) WO2012000113A1 (pt)
ZA (1) ZA201209759B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
FR3004353B1 (fr) * 2013-04-10 2015-05-15 Fabre Pierre Dermo Cosmetique Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine, et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees
KR101800788B1 (ko) * 2017-03-31 2017-11-27 박영오 켈로이드 흉터 개선용 화장료 조성물
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same
CN114767590B (zh) * 2022-04-20 2024-03-15 上海交通大学医学院附属第九人民医院 一种祛疤祛痘印美容液及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740409A (en) * 1980-08-22 1982-03-06 Mitsui Toatsu Chem Inc Remedy for disease caused by extraordinary propagation of collagen
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
CA2383398C (en) * 1999-08-23 2013-06-11 Organogenesis, Inc. Skin care compositions and treatments
WO2002087576A1 (en) * 2001-04-30 2002-11-07 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
RU2234963C2 (ru) * 2002-09-16 2004-08-27 Сибирский государственный медицинский университет Способ лечения гипертрофических и келоидных кожных рубцов
WO2005034980A1 (en) * 2003-09-12 2005-04-21 University Of Colorado Glutamine for use in treating injury
RU2275216C1 (ru) * 2004-12-08 2006-04-27 Елена Григорьевна Арий Способ профилактики формирования патологических кожных рубцов
CA2618600C (en) * 2005-08-11 2017-05-02 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine
WO2007056068A2 (en) * 2005-11-02 2007-05-18 Bentley Pharmaceuticals, Inc. Macrocyclic formulations for transmembrane drug delivery
CN100372522C (zh) * 2005-12-02 2008-03-05 何秋莎 护肤品
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine

Also Published As

Publication number Publication date
HK1183626A1 (en) 2014-02-14
EP2585090A1 (en) 2013-05-01
RU2578426C2 (ru) 2016-03-27
CA2804413A1 (en) 2012-01-05
US20140005116A1 (en) 2014-01-02
MX2013000107A (es) 2013-06-03
KR20130089174A (ko) 2013-08-09
JP2013533867A (ja) 2013-08-29
EP2585090A4 (en) 2014-01-15
AU2011274224A8 (en) 2014-09-18
AU2011274224A1 (en) 2013-01-17
ZA201209759B (en) 2014-03-26
CN103002903B (zh) 2015-04-22
RU2013103507A (ru) 2014-08-10
CO6680624A2 (es) 2013-05-31
WO2012000113A1 (en) 2012-01-05
CN103002903A (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
BR112012033349A2 (pt) tratamento de queloide
BR112015010772A2 (pt) composição de enxágue tópica, uso de uma composição e método para tratar ou melhorar a pele de um indivíduo contra a acne
BR112015008447A2 (pt) métodos para tratar câncer
BR112016014271A2 (pt) composições tópicas em gel incluindo polímero de poli(monoestearoil glicerol-co-succi¬nato) e métodos para aprimorar a aplicação tópica de um agente de benefício
BR112012006891A2 (pt) formulação de hydrogel compreendendo uma solução aquosa com potencial oxidativo redutivo
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
EA201170876A1 (ru) Применение способной к вспениванию композиции, по существу, не содержащей фармацевтически активные ингредиенты, для лечения кожи человека
EP2575884A4 (en) APPLICATIONS AND COMPOSITIONS FOR THE TREATMENT OF ACNE INVERSA
AR092330A1 (es) Composiciones, metodos de absorcion transmucosa y metodo de tratamiento
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112012030261A2 (pt) nova composição farmacêutica sinergística para a preparação de formulações tópicas para a pofilaxia e tratamento de feridas, feridas por queimaduras, exertos de pele, úlceras de pressão e úlceras do pé diabético
BR112014024793A2 (pt) método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica.
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
MX2015010404A (es) Composiciones y metodos para tratamiento y reparacion de tendones.
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112015013374A2 (pt) dispositivo de luva hemostática e método para uso do mesmo
MX2014000150A (es) Sistemas, metodos y formulaciones para tratamiento de cancer.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
BR112013003846A2 (pt) métodos de tratamento de celulite
BRPI0906049A8 (pt) método para determinar se um câncer em um paciente é resistente ao tratamento com um agente antimitótico, método para tratar um paciente com câncer que é resistente ao agente antimitótico e método de tratamento
BR112013024606A2 (pt) composição, kit farmacêutico, e, métodos para o tratamento de uma condição de pele, e para preparar uma composição
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]